Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Di Lorenzo, Giuseppe ^a   Buonerba, Carlo ^a   Federico, Piera ^a   Perdonà, Sisto ^b   Aieta, Michele ^c   Rescigno, Pasquale ^a   D'Aniello, Carmine ^a   Puglia, Livio ^a   Petremolo, Antonella ^a   Ferro, Matteo ^b   Marinelli, Alfredo ^a   Palmieri, Giovannella ^a   Sonpavde, Guru ^d   Mirone, Vincenzo ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UO Oncologia Ospedale Oncologico Regionale   (Italy)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Advanced penile cancer; Chemotherapy; Cisplatin based regimen

Indexed keywords

CISPLATIN; FLUOROURACIL; NARCOTIC ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INOPERABLE CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PAIN; PENIS AMPUTATION; PENIS CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; ITALY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PENIS TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; ITALY; MALE; MIDDLE AGED; NEOPLASM STAGING; PENILE NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876454804     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11453.x     Document Type: Article

References (22)

1. Pizzocaro G, Algaba F, Horenblas S et al. EAU penile cancer guidelines 2009. Eur Urol 2010 ; 57 : 1002-12
2. Ficarra V, Akduman B, Bouchot O, Palou J, Tobias-Machado M. Prognostic factors in penile cancer. Urology 2010 ; 76 : 66-73
3. Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001 ; 91 : 2315-21
4. Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010 ; 76 : 58-65
5. Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman CA Jr, Costanzi JJ. cis- Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol 1989 ; 141 : 66-7
6. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992 ; 147 : 630-2
7. Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 1990 ; 65 : 433-8
8. Power DG, Galvin DJ, Cuffe S et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol 2009 ; 27 : 187-90
9. Theodore C, Skoneczna I, Bodrogi I et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008 ; 19 : 1304-7
10. Di Lorenzo G, Buonerba C, Federico P et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010 ; 58 : 906-11
11. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 ; 45 : 228-47
12. Sobin LH, Gospodariwics M, Wittekind C. TNM Classification of Malignant Tumors. UICC International Union Against Cancer, 7th edn. Hoboken, New Jersey, USA : Willy-Blackwell, 2009 : 239-42
13. Buonerba C, Federico P, D'Aniello C et al. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemother Pharmacol 2011 ; 67 : 1455-61
14. Haas GP, Blumenstein BA, Gagliano RG et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999 ; 161 : 1823 - 5
15. Pagliaro LC, Williams DL, Daliani D et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010 ; 20 : 3851-7
16. Di Lorenzo G, Federico P, Buonerba C et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase II study. Eur Urol 2011 ; 60 : 1280-4
17. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009 ; 55 : 546-51
18. Thuret R, Sun M, Abdollah F et al. Tumor grade improves the prognostic ability of American Joint Committee on Cancer stage in patients with penile carcinoma. J Urol 2011 ; 185 : 501-7
19. Rescigno P, Matano E, Raimondo L et al. Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. Anticancer Drugs 2012 ; 23 : 573-7
20. Necchi A, Nicolai N, Colecchia M et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2011 ; 29 : 650-2
21. Lavens N, Gupta R, Wood LA. EGFR overexpression in squamous cell carcinoma of the penis. Curr Oncol 2010 ; 17 : 4-6
22. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008 ; 359 : 1116-27